Professor of Medicine, University Ark
Hematology
Dr. Bart Barlogie, MD
|
|
Give Review
Bart Barlogie is an expert in the field of Hematology. He received awards:"CMS Meaningful Use Stage 1 Certification", "America's Top Doctors", "America's Top Doctors for Cancer" and "Elected Member". Bart Barlogie, MD is a published doctor. He has 62 publications published. The most current publication "Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?" Bart Barlogie accepts Medicare payments and is listed with Medicare.gov.
Publications
- Monoclonal antibody therapy in multiple Myeloma: where do we stand and where are we going?
- Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.
- The clinical value of molecular subtyping multiple Myeloma using gene expression profiling.
- A common genetic variant in 19q13·3 is associated with outcome of multiple Myeloma patients treated with Total Therapy 2 and 3.
- The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple m...
- Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple Myeloma.
- Phase II study of pomalidomide in high risk relapsed and refractory multiple Myeloma.
- Ex Vivo-expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients.
- Curing Myeloma at last: defining criteria and providing the evidence.
- CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone Disease.
- Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related Disorders: consensus from the Seventh International Workshop on WM.
- The future of autologous stem Cell transplantation in myeloma.
- A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple Myeloma: SWOG S0434.
- Muscular Relapse in a Patient With Multiple Myeloma.
- Artesunate overcomes drug resistance in multiple Myeloma by inducing mitochondrial stress and non-caspase apoptosis.
- In multiple Myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.
- Can autologous bone marrow transplantation improve systolic function in patients with multiple Myeloma related cardiac amyloidosis?
- Serial exome analysis of Disease progression in premalignant gammopathies.
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk Disease.
- A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis.
- Second primary malignancies with lenalidomide therapy for newly diagnosed Myeloma: a meta-analysis of individual patient data.
- Analysis of CD34+ Cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collect...
- Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma.
- Clinical, genomic and imaging predictors of Myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
- The clinical significance of cereblon expression in multiple Myeloma.
- Successful Treatment of Bing-Neel Syndrome Using Intrathecal Chemotherapy and Systemic Combination Chemotherapy Followed by BEAM Auto-Transplant: A Case Report and Rev...
- Hematopoietic progenitor Cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting gr...
- Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk Myeloma: analysis of SWOG trial S0115.
- TRIM13 (RFP2) downregulation decreases tumour Cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.
- Metronomic therapy is an effective salvage treatment for heavily pretreated relapsed/refractory multiple Myeloma.
- Risk Factors for MDS and Acute Leukemia Following Total Therapy 2 and 3 for Multiple Myeloma.
- Role of Bruton's tyrosine kinase (BTK) in myeloma Cell migration and induction of bone disease.
- Combining fluorescent in Situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.
- Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels.
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma Cell growth and osteoclast activity.
- Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple Myeloma treated with Total Therapy 3.
- Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.
- Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine.
- Primary plasma cell Leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols.
- Prognostic implications of cumulative dosing in total therapy 3.
- Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1.
- Cure models as a useful statistical tool for analyzing survival.
- Proteasome inhibitors and bone Disease.
- Improvement in long-term outcomes with successive Total Therapy trials for multiple Myeloma: are patients now being cured?
- Extramedullary Disease portends poor prognosis in multiple myeloma and is overrepresented in high risk Disease even in era of novel agents.
- Second malignancies in total therapy 2 and 3 for newly diagnosed multiple Myeloma: influence of thalidomide and lenalidomide during maintenance.
- Prediction of cytogenetic abnormalities with gene expression profiles.
- Highly activated and expanded natural killer Cells for multiple myeloma immunotherapy.
- Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple Myeloma.
- Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related Disorders.
- Long-term survival in Waldenstrom Macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.
- Mobilization of peripheral blood stem Cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
- An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple Myeloma.
- Seven-year median time to progression with thalidomide for smoldering Myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic dis...
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in Myeloma patients with metaphase cytogenetic abnormalities.
- Primary Myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.
- Cardiac complications in relapsed and refractory multiple Myeloma patients treated with carfilzomib.
- Translating a gene expression signature for multiple Myeloma prognosis into a robust high-throughput assay for clinical use.
- Hepatitis B reactivation in patients with multiple Myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance.
- Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple Myeloma.
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors
- America's Top Doctors for Cancer
- Elected Member
Drug Facts
| NPI NUMBER | 1447340922 | |
| NPPES Provider LastName | BARLOGIE | |
| NPPES Provider FirstName | BART | |
| NPPES Provider ZIPCode | 722057101 | |
| NPPES Provider State | AR | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 5354.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 258.0 | |
| Percent Opioid Claims | 4.82 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1447340922 |
| Last Name Of The Provider | BARLOGIE |
| First Name Of The Provider | BART |
| View All |
Similar Doctors
|
|
Dr. Anne-Marie Maddox, MD |
|
|
Dr. Ahmed M. Alwbari, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daisy V. Alapat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brent C. Staggs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brad P. Baltz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan A. Kemp, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven A. Schichman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kumudini N. Vardhineni, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Natasa Milojkovic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rashid Z. Khan, MD |
|
|
Dr. Zhifu Xiang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeanette M. Ramos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Imran Ahmad, MD |
|
|
Dr. Ahmad M. Safar, MD |
|
|
Dr. Ila Bansal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angela Pennisi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yogesh S. Jethava, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Rangaswamy M. Govindarajan, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah Waheed, MD |